Agoracom Blog Home

Posts Tagged ‘CBD’

« Older Entries
Newer Entries »

Tetra Bio-Pharma $TBP.ca Signs Landmark Commercialization Term Sheet for its Lead Pharmaceutical Product, PPP001, in Israel #MMJ #Marijuana $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:14 AM on Tuesday, April 24th, 2018

Logo tetrabiopharma rgb web

  • Company has signed a first binding term sheet for the marketing and distribution of PPP001 in Israel with Kamada Ltd
  • Signing of a Definitive Distribution Agreement is expected to follow shortly
  • PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription

OTTAWA, ONTARIO–(April 24, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), announced today that the Company has signed a first binding term sheet for the marketing and distribution of PPP001 in Israel with Kamada Ltd., a leading pharmaceutical company. The signing of a Definitive Distribution Agreement is expected to follow shortly. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.

This first international market commercialization agreement represents a significant milestone and a validation of Tetra Bio-Pharma’s business model with a leading Israel-based pharmaceutical company. Israel, like Canada, is considered one of the world leaders in the production and development of cannabinoid-based products. Kamada is a company with two FDA-approved products and an Israeli-based distribution segment that has demonstrated continued growth. Tetra Bio-Pharma intends to work closely with Kamada as PPP001 advances towards regulatory approval and commercial launch in Israel.

Under the terms of the anticipated final agreement, Kamada will be responsible for registering the product, as well as all marketing and distribution, in Israel. Tetra will be eligible to receive certain milestone payments and an undisclosed percentage of the sales of PPP001 generated by Kamada in Israel.

About PPP001 

On April 4, 2018, Tetra Bio-Pharma officially started the Phase 3 trial for PPP001 indicated for terminal stage cancer patients with a goal to improving the quality of life of these patients as well as minimizing their pain. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.

About Tetra Bio-Pharma: Tetra Bio-Pharma (TSX VENTURE:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. Tetra Bio-Pharma is currently developing a pipeline of five cannabinoid-based products using different delivery systems such as smokable pellets, oral tablets, eye drops and topical ointments. More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Robert (Bob) Béchard
Vice President Finance and Business Development
[email protected]
M: +1 514 817-2514

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: +1 514 840 7990
M: +1 514 232 1556

Tags: , , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Signs Landmark Commercialization Term Sheet for its Lead Pharmaceutical Product, PPP001, in Israel #MMJ #Marijuana $AERO $CBDS $CGRW $APH.ca $GBLX

Namaste Receives Conditional Approval to List on TSX Venture Exchange $N.ca $NXTTF $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 9:22 AM on Thursday, April 19th, 2018

Nlogo

  • Received conditional approval to list the common shares and warrants of the Company on the TSX Venture Exchange as a Tier 1 issuer
  • listing is subject to the Company fulfilling certain requirements of the TSXV in accordance with the terms of its conditional approval letter dated April 18th, 2018

VANCOUVER, British Columbia, April 19, 2018 — Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has received conditional approval to list the common shares and warrants of the Company on the TSX Venture Exchange (“TSXV”) as a Tier 1 issuer. The listing is subject to the Company fulfilling certain requirements of the TSXV in accordance with the terms of its conditional approval letter dated April 18th, 2018. The Company anticipates that the common shares will continue to trade under the trading symbol “N” and its warrants will continue to trade under the symbol “N.WT.”

The Company will proceed expeditiously to satisfy these conditions and management is confident that all conditions for listing will be met. Upon obtaining final approval, the Company will issue a further press release to inform shareholders when it anticipates that its common shares and warrants will commence trading on the TSXV.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: “We are very pleased to have received conditional approval from the TSXV. We’re also proud to have been accepted as a Tier 1 issuer. We believe that this listing will provide the company and its shareholders with many advantages, including greater visibility and enhanced market access for Canadian and international investors. We’re extremely proud to join the ranks of many innovative cannabis companies in our industry and gain new exposure through a larger exchange. We will remain committed to expanding our business strategy through innovation to help solidify our position in the cannabis sector.

I’d like to take this opportunity to thank the Canadian Securities Exchange (“CSE”) for their tremendous support. We greatly appreciate the CSE for providing us with a platform for Namaste to grow and we’re excited to be moving forward towards the anticipated TSXV listing.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis sales licence (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

 

Further information on Namaste and its products can be accessed through the links below:

namastetechnologies.com

namastevapes.ca

everyonedoesit.ca

namastevaporizers.co.uk

everyonedoesit.co.uk

australianvaporizers.com.au

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.

Tags: , , , , ,
Posted in All Recent Posts, Namaste Technologies Inc. | Comments Off on Namaste Receives Conditional Approval to List on TSX Venture Exchange $N.ca $NXTTF $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Marijuana Company of America’s $MCOA Joint Venture Completes Set-up of 7,000 Sq. Ft. Greenhouse Facility in Washington State $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:14 AM on Wednesday, April 18th, 2018

15233 mcoa

  • Completed the construction of three greenhouses totaling 7,000 square feet
  • Represents the completion of more than 23% of the total 30,000-square-foot cultivation facility

Escondido, California–(April 18, 2018) – MARIJUANA COMPANY OF AMERICA INC.  (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce that its joint venture project, BV-MCOA Management, LLC, has completed the construction of three greenhouses totaling 7,000 square feet. This represents the completion of more than 23% of the total 30,000-square-foot cultivation facility.

The Company entered into the joint venture agreement with Bougainville Ventures, Inc. on March 16, 2017, and subsequently arranged for $800,000 funding for the purchase of the land and the construction of the greenhouses. Transfer of ownership of the property to the joint venture is pending completion of the final subdivision of the property by the Okanogan County Assessor.

The construction team constructed a total of 7,000 sq. ft. in greenhouse space in preparation for the 2018 planting season. Final inspection of the security system and greenhouse construction is expected to be completed in the coming weeks. Once the final inspection is approved, the licensed tenant can occupy the facility and begin cultivation.

Donald Steinberg, MCOA CEO said, “We are pleased to see the completion of the first phase of the greenhouse facilities. Once the security system is in place, we are confident the site will pass final inspection allowing our tenant-growers to occupy the facility and begin operations. MCOA continues to explore opportunities to replicate this business model and expand our real estate portfolio.”

The joint venture will lease the turnkey property to a licensed tenant, thereby acting solely as a landlord. As a turnkey landlord, the joint venture aims to provide an ideal cultivation environment for its future tenant, and it is anticipated that greenhouse will be completed by the beginning of Q3 2018. The completed 30,000 square foot cultivation facility will have a capacity of approximately 4,000 plants.

About Bougainville Ventures, Inc. 
Bougainville Venture Inc. is in the core business of converting irrigated farmland that was traditionally used to grow marginally profitable feed crops, to greenhouse-equipped farmland used to grow luxury crops with a primary focus on marijuana. Bougainville is an agricultural services company that focuses on providing growers with state-of-the-art computer controlled greenhouses and processing facilities. Bougainville offers fully built out turnkey solutions to licensed tenant-growers and luxury crop growers who will lease the facilities for production and processing. Bougainville does not “touch the plant” and only provides growing infrastructure as a landlord for licensed marijuana growers.

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About BV-MCOA Management, LLC
On March 16, 2017, the Company and Bougainville Ventures, Inc. entered into a joint venture agreement that included the purchase of land in Washington State, and plans to build out facilities on the land to support leased agricultural growth, including licensed cannabis operators. As amended on November 6, 2017, the Company’s financial commitment to the joint venture was fixed at contributing $800,000, and the issuance of 15 million shares of restricted common stock to Bougainville. The Company completed its payment on November 9, 2017. The funding arranged for by the Company provided consideration for the purchase of the land and contributed to the build out of the facility. The land is pending legal transfer to the joint venture after subdivision is completed by the Okanogan County Assessor. The Company and Bougainville are currently revising and restating their joint venture agreement to resolve certain discrepancies and inconsistencies. The Company and Bougainville expect to complete this restatement shortly and once completed, the Company will disclose it on Form 8-K filed with the Securities and Exchange Commission. For more information about MCOA and BV-MCOA Management, Inc., please refer to the Company’s disclosures with the Securities and Exchange Commission (www.sec.gov).

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , , , ,
Posted in All Recent Posts, Marijuana Company of America | Comments Off on Marijuana Company of America’s $MCOA Joint Venture Completes Set-up of 7,000 Sq. Ft. Greenhouse Facility in Washington State $AERO $CBDS $CGRW $APH.ca $GBLX

Tetra Bio-Pharma $TBP.ca Clinical Study on Cannabis Oil Capsules for Patients Suffering from Chronic Pain should be completed by Fall 2018 $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:05 AM on Thursday, April 12th, 2018

Logo tetrabiopharma rgb web

  • Provides a status report on its encapsulated cannabis oils (PPP005) clinical trials and that these cannabis products are ready to commercialize in the retail market post-legalization
  • authorization from the Office of Controlled Substances marks the initiation of the treatment phase of the Phase 2 clinical trial that will be used to support Product License Applications post legalization
  • Tetra is performing this clinical study to obtain safety and efficacy data to support modern claims for the use of encapsulated cannabis oils in the treatment of chronic pain

OTTAWA, ONTARIO–(April 12, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), provides a status report on its encapsulated cannabis oils (PPP005) clinical trials and that these cannabis products are ready to commercialize in the retail market post-legalization.

Natural health products and OTC medications

The authorization from the Office of Controlled Substances marks the initiation of the treatment phase of the Phase 2 clinical trial that will be used to support Product License Applications post legalization. Tetra is performing this clinical study to obtain safety and efficacy data to support modern claims for the use of encapsulated cannabis oils in the treatment of chronic pain. Tetra’s program is designed to build a leading position in the development and commercialization of cannabis-based natural health products. Tetra’s products are being developed to be compliant with standards expected for pharmaceutical products which will be supported by scientific and clinical evidence.

PPP005 Phase 1 Clinical trial

Phase 1 clinical trial to assess safety, tolerability and pharmacokinetics of single and multiple dose of encapsulated cannabis oil (10 mg THC with 10 mg CBD) will be completed soon. “This study will provide cardiovascular safety data to ensure that the oil formulations can be safely used by consumers. The pharmacokinetic data will provide the data required to define the frequency of dosing needed to avoid inappropriate use that could lead to accumulation of cannabinoids in the body,” said Dr. Guy Chamberland, M.Sc., Ph.D., interim CEO and Chief Scientific Officer.

PPP005 Phase 2 Clinical trial

On March 22, 2018, Santé Cannabis, the Montreal-based clinic that is conducting the Phase 2 clinical trial for Tetra, received authorization from the Office of Controlled Substances to use the cannabis oil capsules of PPP005 (controlled substance).

This authorization allowed the Principal Investigator of the trial, Dr. Antonio Vigano, to proceed with the clinical trial of PPP005 in chronic pain patients. This exemption allows Santé Cannabis to prescribe the blinded study medication and for Aphria Inc to ship blinded products to patient’s home under the jurisdiction of the ACMPR. The screening and enrolment is proceeding faster than expected and will allow Tetra to meet its corporate objectives.

“We are performing this Phase 2 clinical trial to obtain safety and efficacy data to help drive the sales of encapsulated cannabis oil products for the treatment of chronic pain,” added Dr. Guy Chamberland. “We expect chronic pain patients to use cannabis oils, but many of these patients will also be taking opioids or other prescription medications. The capability of different doses and ratios of medical cannabis oil to change the amount and type of concomitant medications, such as opioids, used for pain, and the need for rescue pain medication to control chronic non-cancer and cancer pain is evaluated. The use of measures that quantify different pain drug regimens used by the patients will help us understand the potential of cannabis oils to be used for opioid sparing. The trial should be completed by fall 2018.”

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. Tetra Bio-Pharma is currently developing a pipeline of five cannabinoid-based products using different delivery systems such as smokable pellets, oral tablets, eye drops and topical ointments.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
[email protected]
(514) 360-8040 Ext. 210

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: 1 514 840 7990
M: 1 514 232 1556

Tags: , , , ,
Posted in Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Clinical Study on Cannabis Oil Capsules for Patients Suffering from Chronic Pain should be completed by Fall 2018 $AERO $CBDS $CGRW $APH.ca $GBLX

#Marijuana stocks just got less risky, GMP Securities says $N.ca $NXTTF.ca $TBP.ca $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 12:41 PM on Monday, March 26th, 2018

  • Recent developments on the political and regulatory end are likely to add stability to the emerging market, says Martin Landry, analyst with GMP Securities
  • Canada is poised to be an global leader in the cannabis space
  • This past Thursday saw Canada’s Senate voting on its second reading of Bill C-45, the so-called Cannabis Act which would legalize the recreational use of marijuana
  • bill passed 44 to 29

March 25, 2018 By Jayson MacLean

Canada’s still-developing cannabis sector has seen its share of fortunes won and lost over the past year, with stock prices skyrocketing in a matter of weeks over December and January, only to pull back considerably in the time since.

But recent developments on the political and regulatory end are likely to add stability to the emerging market, says Martin Landry, analyst with GMP Securities, who says Canada is poised to be an global leader in the cannabis space.

This past Thursday saw Canada’s Senate voting on its second reading of Bill C-45, the so-called Cannabis Act which would legalize the recreational use of marijuana. Although the vote was predicted to be tight, as some senators in favour of the legislation were out of Ottawa on committee work and Conservative senators promising to vote en masse against, the bill nevertheless passed 44 to 29.

That bodes well for the bill, says Landry, who projects a late summer/early fall opening up of the rec cannabis market.

“[The Senate vote] provides a positive read-through in our view for the potential outcome of the final third reading vote, as the majority of the Independent Senators Group appear to be aligned with the Liberals,” Landry said in a note to clients on Friday. “In a 3rd reading scenario where all Liberals and Conservatives vote for and against Bill C-45 respectively, this would suggest ~73 per cent of independents (versus 95 per cent at second reading) would need to vote in favour for Bill C-45 to become law.”

As well, this past week Health Canada released its fourth quarter 2017 data on medical marijuana use, finding that patient registrations were up 14 per cent on the quarter to 269,502, while total volume of medical cannabis grew around 10 percent on the quarter and around 34 per cent year-over-year, the best growth rate over the past three quarters, says Landry.

Also coming from Health Canada were summary results from public consultations on the new cannabis regulations, held during a 60-day period starting this past November. The consultations drew in approximately 4,000 responses, covering all aspects of the proposed regulations including licensing and permits, security clearance and cannabis tracking, product packaging and labelling and the medical use of cannabis.

Some notable results include strong support from respondents for a quick roll-out on regulations regarding cannabis edibles along with majority support for the government’s plans concerning licensing and product labelling and plain packaging.

Landry says that going forward the report should feed into guidance and regulations for industry participants. On the issue of product labelling, the analyst says that Health Canada’s push for plain packaging could make it “difficult for licensed producers to differentiate their brands on the basis of packaging, however advertising rules are not expected to be more restrictive than those for tobacco,” Landry says.

In all, Landry sees the ramped up medical market and the maturing regulatory landscape to be a win for Canadian companies, who now have a head start over the competition when it comes to the industrial production of cannabis within a tightly regulated environment.

Landry says that having LPs required to deliver secure and stable production has “led Canadian licensed producers to build pharmaceutical grade production facilities, develop solid cultivation know-how and create a large bank of genetics,” he says. “Combined with well capitalized balance sheets, we believe that Canadian LPs are well positioned to become global leaders in the cannabis sector.”

Source: https://www.cantechletter.com/2018/03/marijuana-stocks-just-got-less-risky-gmp-securities-says/

Tags: , , , , ,
Posted in All Recent Posts, Featured, Marijuana Company of America, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on #Marijuana stocks just got less risky, GMP Securities says $N.ca $NXTTF.ca $TBP.ca $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Tetra Bio-Pharma $TBP.ca Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc. $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:13 AM on Monday, March 19th, 2018

Logo tetrabiopharma rgb web

  • Announced the completion of the previously announced acquisition of the remaining 20% interest in its PhytoPain Pharma Inc. subsidiary
  • Transaction is an important milestone for Tetra Bio-Pharma and all our stakeholders

OTTAWA, ONTARIO–(March 19, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the completion of the previously announced acquisition of the remaining 20% interest in its PhytoPain Pharma Inc. subsidiary (the “Transaction“) from entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the “Sellers“).

“The Transaction is an important milestone for Tetra Bio-Pharma and all our stakeholders,” said Bernard Fortier, Tetra’s CEO. “It allows Tetra to gain 100% control of PhytoPain Pharma, a key asset in the development of our pipeline of cannabinoid-based drugs and gives Tetra full flexibility to enter into other partnerships or agreements in the future.”

The purchase price for the Transaction was comprised of a combination of cash, promissory notes and common shares of Tetra, some of which will be released to the Sellers upon the achievement of key milestones. The terms of the Transaction are detailed in the Corporation’s news release dated January 2, 2018 which is available on SEDAR under the Corporation’s profile. The Corporation used $500,000 out of the proceeds from the recently completed bought deal offering to repay a portion of the principal amount owing to the Sellers under the promissory notes.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™ product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™ product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575

For investors information, please contact:
[email protected]
(438) 504-5784

Tags: , , , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc. $AERO $CBDS $CGRW $APH.ca $GBLX

Tetra Bio-Pharma $TBP.ca Announces #FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:30 AM on Wednesday, March 14th, 2018

Logo tetrabiopharma rgb web

  • Announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to the active ingredients of its PPP001 drug for the treatment of complex regional pain syndrome 
  • FDA Orphan Drug Designation program provides orphan status to drugs intended to treat rare diseases or disorders that affect less than 200,000 people in the USA
  • Gives Tetra a seven-year marketing exclusivity, after drug approval by the FDA

OTTAWA, ONTARIO–(March 14, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the active ingredients of its PPP001 drug (delta-9-tetrahydrocannabinol 9.5% and cannabidiol 2.5%) for the treatment of complex regional pain syndrome (CRPS). The Orphan Drug Designation was granted for the active moiety of the drug PPP001 and not the formulation.

The FDA Orphan Drug Designation program provides orphan status to drugs intended to treat rare diseases or disorders that affect less than 200,000 people in the USA. This designation gives Tetra a seven-year marketing exclusivity, after drug approval by the FDA, and provides Tetra potential incentives such as access to federal grants and tax credits as well as a waiver of Prescription Drug User Fee Act filing fees.

Tetra successfully completed a placebo-controlled Phase 1a and 1b study of PPP001 in healthy volunteers and demonstrated that PPP001 can be safely consumed. “We are pleased to receive FDA Orphan Drug Designation for PPP001 and we look forward to discussing the clinical program with the US FDA that will be used to demonstrate the safety and efficacy in patients suffering from CRPS,” said Guy Chamberland, M.Sc., Ph.D., Chief Scientific Officer of Tetra.

According to the USA National Institute of Health, “complex regional pain syndrome (CRPS) is a chronic pain condition that most often affects one limb (arm, leg, hand, or foot) usually after an injury. CRPS is believed to be caused by damage to, or malfunction of, the peripheral and central nervous systems. CRPS is characterized by prolonged or excessive pain and changes in skin color, temperature, and/or swelling in the affected area.”

Appointment of a New Director – Tetra also announced the appointment of a new Director, Mr. Benoit Chotard, effective immediately. Mr. Chotard was previously a member of the Board of Directors from September 2016 to July 2017, he left for personal reasons, no longer applicable, and is pleased to come back. “We are glad to welcome back Mr. Chotard to the board and we look forward to working closely with him in building Tetra as a leading biopharmaceutical organization,” said Andre Rancourt, Chairman of Tetra Bio-Pharma. “Mr. Chotard’s tremendous experience as an advisor of publicly listed companies will be a huge addition to our team. His local and international network will be a key factor in the Company’s growth.”

Benoit Chotard is a corporate finance & development executive who has over 20 years of international corporate finance, management and public market expertise. Previously, Mr. Chotard was employed as managing partner at Capital Force United, as President & CEO, and Director of Orletto Capital Inc., Vice-president Corporate Development for Pakit Inc., Senior Vice-president Finance Corporate Development and acting as Chief Financial Officer for CANTRONIC Systems (Canada) Inc., Vice-President Chief Financial Officer of Victhom Human Bionics, and spent eight years as Head of the Technology Investment Group of National Bank Financial Inc.

Mr. Chotard has been a Member of “Ordre des ingénieurs du Québec” since 1989 and obtained a bachelor’s degree in Chemical Engineering (1989) and a MBA (1993) from the Université de Sherbrooke.

About PPP001:

PPP001 aims to be the first smokable marihuana for advanced cancer pain under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9.5% THC and 2.5% CBD.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™ product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™ product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: 1 514 840 7990 / M: 1 514 232 1556

For investors information, please contact:
[email protected]
(438) 504-5784

Tags: , , , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Announces #FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome $AERO $CBDS $CGRW $APH.ca $GBLX

Marijuana Company of America $MCOA Announces the Offical Launch of Benihemp at the ASD Trade Show $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:04 AM on Monday, March 12th, 2018

15233 mcoa

  • Announce the official launch of Convenient Hemp Mart, LLC’s “Benihemp” branded CBD products at ASD Market Week,
  • One of the largest business-to-business trade shows in the world.

Escondido, California–(March 12, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce the official launch of Convenient Hemp Mart, LLC’s “Benihemp” branded CBD products at ASD Market Week, one of the largest business-to-business trade shows in the world.

Convenient Hemp Mart has developed a collection of Benihemp branded, sample sized products for consumers including topicals, tinctures, and edibles packaged in 1-day, 2-day, and 30-day supplies. The target markets are convenience stores, smoke shops, gas stations and similar types of retail businesses where CBD commerce has a greater likelihood of generating sales from the impulse buyer at the register.

Convenient Hemp Mart is officially launching the Benihemp product line at ASD Market Week (www.asdonline.com) in Las Vegas, NV. ASD is a comprehensive business-to-business trade show for retail merchandise that annually hosts 45,000 buyers from over 90 countries, representing major department stores, convenience stores, gift shops, grocery stores, and other retail stores. Out of the 45,000 attending the show, 98% of the attendees have purchasing power, and the average buyer spends a total of $82,500 on product orders per show. Benihemp will be located in the lower south hall at booth SL2449.

MCOA has invested $100,000 into Benihemp in exchange for a 25% equity stake in Convenient Hemp Mart, LLC.

Donald Steinberg CEO of MCOA stated “Marijuana Company of America is excited for the opportunity to diversify product distribution into retail markets across the country. We believe in the Convenient Hemp Mart team and their ability to successfully launch Benihemp at ASD.”

“We are eagerly looking forward to the unveiling of the Benihemp brand at this ASD Marketplace event. With the ever-growing Convenience store marketplace hitting a new record of over 140 billion dollars in annual sales last year, we believe this is the perfect place to present the first industrial Hemp derived products developed specifically for this market. Our team has worked very diligently for the launch of the Benihemp brand and are all thrilled that it has finally come to life,” said Sam Girges of Benihemp.

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our Benihemp Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , , , , , ,
Posted in Marijuana Company of America, Medical Marijuana Stocks | Comments Off on Marijuana Company of America $MCOA Announces the Offical Launch of Benihemp at the ASD Trade Show $AERO $CBDS $CGRW $APH.ca $GBLX

Tetra Bio-Pharma $TBP.ca Announces the Completion of GrowPros Transaction $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 12:16 PM on Thursday, February 22nd, 2018

Logo tetrabiopharma rgb web

 

 

  • Completion of the sale of its shares of GrowPros MMP Inc. (“GrowPros”) to North Bud Farms Inc.
  • Cash proceeds will be used to further strengthen Tetra’s balance sheet and, most importantly, allow the Company to focus its activities on drug development and clinical trials of its pharmaceutical business.

OTTAWA, Feb. 22, 2018 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce the completion of the sale of its shares of GrowPros MMP Inc. (“GrowPros”) to North Bud Farms Inc.  (the “Purchaser” or “North Bud”) as previously announced in Tetra’s December 21st, 2017 press release.

Transaction Details
As previously disclosed, Tetra will receive total proceeds in the amount of $350,000, including an initial $175,000 that was paid in December 2017, as well as 15,000,000 common shares of the Purchaser, representing approximately 41% of the Purchaser’s currently issued and outstanding share capital. It remains Tetra’s intention to have such shares be transferred to its shareholders as a dividend in kind on a pro-rata basis, concurrently with the proposed initial public offering of the Purchaser and listing of the shares of the Purchaser on a recognized Canadian stock exchange. The transaction is structured as a sale with a resolutory condition whereby, in the event that the initial public offering of the Purchaser is not completed prior to June 30, 2018 (or such other date as may be agreed upon by the Corporation and the Purchaser), the sale of the shares of GrowPros will be deemed to have never occurred and title to the shares of GrowPros will revert back to Tetra, and in turn GrowPros would then remain a wholly-owned subsidiary of Tetra.

As part of the transaction, North Bud has agreed to advance GrowPros’ late stage ACMPR application (submitted in November 2014) through the application process with Health Canada. In addition, the Purchaser intends to begin the phase 1 build out of a 50,000-square foot GMP grade indoor production facility in late Q1 2018. The facility is located on 130 acres of agricultural land in Venosta, Quebec (40 min north of Ottawa).  The Purchaser believes that the property can be developed into a total of 1.5 million square feet of production space. The parties intend to enter into an agreement shortly so that Tetra will be granted access to future licenced cannabis production by GrowPros, securing another source of pharmaceutical GMP quality cannabis.

The cash proceeds will be used to further strengthen Tetra’s balance sheet and, most importantly, allow the Company to focus its activities on drug development and clinical trials of its pharmaceutical business. Tetra expects this transaction to generate long-term shareholder value by ensuring another supply of cannabis with pharmaceutical GMP quality for the pipeline of products under development.

Management Statement
“This is an important transaction for Tetra and our shareholders. Not only have we monetized an asset that brings immediate cash into the business but we also have an equity stake in North Bud that we intend to distribute to our shareholders. Of course, long term, securing an additional steady supply of dried cannabis is hugely beneficial for our pharmaceutical development programs. Finally, I am very excited that North Bud will be pushing forward the ACMPR application with Health Canada. This is a great day for all parties involved!”  Says Bernard Fortier, CEO of Tetra.

About North Bud Farms:
North Bud is a partially owned subsidiary of North Bud Capital Holdings Ltd. North Bud intends to apply for a listing on a recognized Canadian stock exchange in Q2 2018. North Bud, in addition to its newly-acquired ownership of GrowPros, will be focused on GMP standardized pharma grade cannabis production as well as food grade cannabinoid infused inputs for both the international pharmaceutical market and the pending consumer goods and consumables segment of the recreational cannabis market.

About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma

For further information, please contact Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
[email protected]
1 (438) 899-7575

Tags: , , , , ,
Posted in All Recent Posts, Featured, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Announces the Completion of GrowPros Transaction $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Neptune and Tetra Bio-Pharma $TBP.ca Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:27 AM on Monday, February 12th, 2018

Logo tetrabiopharma rgb web

  • Entered into an agreement for the co-development, commercialization and marketing of purified cannabinoid oil-based products
  • Will address pain and inflammation relief applications for the natural health products and pet veterinary markets

LAVAL, QUÉBEC–(Feb. 12, 2018) – Tetra Bio-Pharma Inc. (“Tetra”) (TSX VENTURE:TBP)(OTCQB:TBPMF) and Neptune Technologies & Bioressources Inc. (“Neptune”) (NASDAQ:NEPT)(TSX:NEPT) today announced that they entered into an agreement for the co-development, commercialization and marketing of purified cannabinoid oil-based products to address pain and inflammation relief applications for the natural health products and pet veterinary markets.

“We are proud to partner with a company like Neptune. Their know-how in extraction, performed in a state of the art GMP facility, is a great asset to have for the cannabis medicinal/pharma oil market. This combined to Tetra’s expertise in the development of products for the prescription drug and pharma retail market, makes this partnership truly one of a kind. Leveraging our complementary expertise in research, regulatory affairs, science, formulation, and delivery forms, we intend to commercialize these new products in preparation of the forthcoming retail cannabis market in Canada, and a RX veterinary North American market,” stated Bernard Fortier, Chief Executive Officer (CEO) of Tetra.

”We are excited to partner with Tetra, a biopharmaceutical leader in the development of cannabinoid-based novel drugs and treatments. The products that will be co-developed will be supported by research as well as our unique formulation and delivery system knowledge, which are key components of our mission to deliver differentiated science-based, value-added products,” said Jim Hamilton, President and CEO of Neptune.

The veterinary health care market is expected to reach US $39.7 billion by 2021, registering a CAGR of 8.06% during 2017-2022 (the forecast period)1. Veterinary medicines are associated with treatment, diagnosis, and prevention of diseases among animals. It covers a variety of animal species, both, in domestic and wild.

1 Mordor intelligence October 2017: Veterinary Health Care Market – Growth, Trends and Forecast (2017-2022).About Neptune Technologies & Bioressources Inc.

Neptune is a wellness products company, with more than 50 years of combined experience in the industry. The Corporation formulates and develops turnkey solutions available in various unique delivery forms, offers specialty ingredients such as MaxSimil®, a patented ingredient that may enhance the absorption of lipid-based nutraceuticals, and a variety of other marine and seed oils. Neptune also sells premium krill oil directly to consumers through web sales at www.oceano3.com. Leveraging our scientific, technological and innovative expertise, Neptune is working to develop unique extracts and formulations in high potential growth segments, such as medical and wellness cannabinoid-based products.

Neptune is also pursuing opportunities in the prescription drug markets, through its 20% investment in Acasti Pharma Inc. (“Acasti”). Acasti focuses on the research, development and commercialization of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia.

The Company’s head office is located in Laval, Quebec.

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. More information at: www.tetrabiopharma.com.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Forward-looking information in this press release includes, but is not limited to, information or statements about our ability to successfully develop, produce, supply, promote or generate any revenue from the sale of any cannabis-based products for medical use, as well as the results of any clinical trials associated thereto.

The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement and the “Cautionary Note Regarding Forward-Looking Information” section contained in Neptune’s latest Annual Information Form (the “AIF”), which also forms part of Neptune’s latest annual report on Form 40-F, and which is available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on the investor section of Neptune’s website at www.neptunecorp.com. All forward-looking statements in this press release are made as of the date of this press release. None of Neptune and Tetra undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Neptune’s and Tetra’s public securities filings with the Securities and Exchange Commission and/or the Canadian securities commissions, as applicable. Additional information about these assumptions and risks and uncertainties is contained in the Neptune’s AIF under “Risk Factors” or in Tetra’s MD&A under “Risk Factors”.

Neither NASDAQ, the Toronto Stock Exchange nor the TSX Venture Exchange accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Neptune Technologies & Bioressources Inc. & Tetra Bio-Pharma Inc.

Neptune Wellness Solutions
Mario Paradis
VP & CFO, Neptune
[email protected]
1.450.687.2262 x236

Investor Relations Contact (Canada)
Pierre Boucher
MaisonBrison
1.514.731.0000
[email protected]

Investor Relations Contact (U.S.)
Ed McGregor/Jody Burfening
LHA, IR
1.212.838.3777
[email protected]

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
[email protected]
O: (438) 899-7575

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: 1 514 840 7990 / M: 1 514 232 1556

Tags: , , , ,
Posted in All Recent Posts, Featured, Tetra Bio-Pharma Inc. | Comments Off on Neptune and Tetra Bio-Pharma $TBP.ca Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation $AERO $CBDS $CGRW $APH.ca $GBLX

« Older Entries
Newer Entries »